Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
inflammatory conditions
Biotech
Bolt strikes Prana reverse merger alongside $120M financing
A syndicate of investors is backing Bolt with $120 million upfront and a potential $60 million more through warrants.
Marissa Russo
Oct 23, 2026 9:00am
Celldex ends skin disease program after failing phase 2 test
Jul 22, 2026 6:00am
Merck bags $700M from Blackstone, spends $150M to regain asset
Nov 4, 2025 9:15am
Sitala seals $670M deal for Fosun immune disease drug
Aug 26, 2025 2:44pm
Novartis lines up another potential indication for BTK inhibitor
Mar 9, 2024 12:00pm
MoonLake's IL-17 drug wins 'meet or beat' trial vs. competition
Jun 26, 2023 11:18am